ポスター：ナノボディの次世代シーケンス（NGS）ライブラリーの包括的解析

Genedata Biopharma Partner Symposium 2024, Basel, Switzerland
March 6, 2024

Nanobodies are camelid heavy chain-only antibodies, whose small size makes them easier to engineer while offering distinct therapeutic advantages. Next-generation sequencing (NGS) is emerging as a complementary tool for the analysis of nanobody and antibody libraries selected using phage-display biopanning. The technique leads to a higher yield of potential binders compared to traditional approaches that may yield only a limited number.

Genedata Selector^® supports comprehensive analysis of nanobody NGS libraries, enabling the identification of more specific high-affinity binders within a much larger sequence space. This facilitates the targeting of multiple different antigen epitopes based on complementarity-determining region (CDR) homology, and the generation of backup candidates.